THG-001   (GalliProst)

Ga-68 THP-PSMA single step ‘cold’ kit

Theragnostics’ clinical lead, THG-001 (68Ga-THP-PSMA), is being developed with our proprietary Galli® single-vial kit manufacturing technology to provide valuable diagnostic information on the status of patients with prostate cancer. A Phase I clinical trial of THG-001 was completed during 2016 and results of the trial have been published in the Journal of Nuclear Medicine.

The Phase II trial of THG-001 is now complete. More information about this trial can be found on clinicaltrials.gov here.

A Phase III trial is currently being registered following Theragnostics meeting with the FDA in February 2019.

THG-001   (GalliProst)
Ga-68 THP-PSMA single step ‘cold’ kit

Theragnostics’ clinical lead, THG-001 (68Ga-THP-PSMA), is being developed with our proprietary Galli® single-vial kit manufacturing technology to provide valuable diagnostic information on the status of patients with prostate cancer. A Phase I clinical trial of THG-001 was completed during 2016 and results of the trial have been published in the Journal of Nuclear Medicine.

The Phase II trial of THG-001 is now complete. More information about this trial can be found on clinicaltrials.gov here.

A Phase III trial is currently being registered following Theragnostics meeting with the FDA in February 2019.